Biomed Lublin will provide an anti-TB vax for the Ministry of Health

The director of the Public Procurement Department at the Minister of Health concluded a tender for the supply of an anti-tuberculosis vaccine in 2022 and chose the BCG 10 anti-tuberculosis vaccine produced by Biomed Lublin as the most advantageous – Biomed Lublin announced in a press release.

The order concerns the delivery of 72 thousand. doses with a total value of PLN 4.65 million. Biomed’s partner in the tender is Cefarm Pharmaceutical Center.

The delivery is to be made by the company in three parts, starting from February 28, 2022 to October 28, 2022.

“In the opinion of the management board, the delivery of an anti-tuberculosis vaccine in the course of the tender will be a positive event for the company, due to a significant improvement in the cash flow structure in the following quarters” – it was written in the release.

As Biomed Lublin reported in a press release, the Moreau strain, owned by the Lublin company, has been used in Poland for preventive vaccinations since 1955. Currently, the BCG Biomed Lublin anti-tuberculosis vaccine is delivered to 9 countries outside Poland.

The company announced that it is acquiring new export markets at the same time – in January, the first shipment of Gamma Anty D to Croatia and Onko BCG to Slovenia and the United Kingdom were made.

“Our competitiveness related to the product portfolio, as well as the potential to confront the very high demand for our drugs, bring tangible results. We place great emphasis on increasing the production potential of products in individual departments. This is undoubtedly one of our priorities. Thanks to this, we expect an increase in sales. already this year “- said Maksymilian Świniarski, president of Biomed Lublin, quoted in the press release. PAP Biznes